×
About 9,259 results

ALLMedicine™ Mantle Cell Lymphoma Center

Research & Reviews  4,177 results

Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analys...
https://doi.org/10.1111/bjh.17363
British Journal of Haematology; McCulloch R, Lewis D et. al.

Feb 23rd, 2021 - Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when give...

COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PE...
https://doi.org/10.1097/RLU.0000000000003597
Clinical Nuclear Medicine; Xu G, Lu Y

Feb 16th, 2021 - We present here a 72-year-old man with mantle cell lymphoma who has completed chemotherapy and achieved complete metabolic response to the therapy 10 months ago. Series follow-up FDG PET/CT scans have been negative for lymphoma. Current FDG PET/CT...

Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805322
Blood Advances; Wu W, Wang W et. al.

Feb 11th, 2021 - Inhibition of the B-cell receptor (BCR) signaling pathway is highly effective in B-cell neoplasia through Bruton tyrosine kinase inhibition by ibrutinib. Ibrutinib also disrupts cell adhesion between a tumor and its microenvironment. However, it i...

Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805338
Blood Advances; Maekawa F, Kishimori C et. al.

Feb 11th, 2021 - Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma.|2021|Maekawa F,Kishimori C,Nakagawa M,Takeoka K,Fukutsuka K,|

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation S...
https://doi.org/10.1016/j.clml.2020.09.007
Clinical Lymphoma, Myeloma & Leukemia; Kumar A, Bantilan KS et. al.

Feb 9th, 2021 - Minimal residual disease (MRD) monitoring has been used to identify early molecular relapse and predict clinical relapse in mantle cell lymphoma (MCL). Few published data exist in MCL on the performance of next-generation sequencing-based assay of...

see more →

Guidelines  13 results

FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA

Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL
https://www.onclive.com/conference-coverage/asco-2020/ktex19-demonstrates-comparable-pharmacologic-clinical-outcomes-to-approved-therapies-in-mcl

May 29th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial...

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
http://ascopubs.org/doi/abs/10.1200/JCO.18.00690?journalCode=jco
Gerson,J.,et al

Jan 6th, 2019 - In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our f...

Guideline for the management of mantle cell lymphoma.
https://doi.org/10.1111/bjh.15283
British Journal of Haematology; McKay P, Leach M et. al.

May 16th, 2018 - Guideline for the management of mantle cell lymphoma.|2018|McKay P,Leach M,Jackson B,Robinson S,Rule S,|therapeutic use,prevention & control,methods,pathology,therapy,

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines fo...
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.

Sep 8th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

see more →

Drugs  25 results see all →

Clinicaltrials.gov  4,543 results

Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analys...
https://doi.org/10.1111/bjh.17363
British Journal of Haematology; McCulloch R, Lewis D et. al.

Feb 23rd, 2021 - Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when give...

COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PE...
https://doi.org/10.1097/RLU.0000000000003597
Clinical Nuclear Medicine; Xu G, Lu Y

Feb 16th, 2021 - We present here a 72-year-old man with mantle cell lymphoma who has completed chemotherapy and achieved complete metabolic response to the therapy 10 months ago. Series follow-up FDG PET/CT scans have been negative for lymphoma. Current FDG PET/CT...

Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805322
Blood Advances; Wu W, Wang W et. al.

Feb 11th, 2021 - Inhibition of the B-cell receptor (BCR) signaling pathway is highly effective in B-cell neoplasia through Bruton tyrosine kinase inhibition by ibrutinib. Ibrutinib also disrupts cell adhesion between a tumor and its microenvironment. However, it i...

Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805338
Blood Advances; Maekawa F, Kishimori C et. al.

Feb 11th, 2021 - Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma.|2021|Maekawa F,Kishimori C,Nakagawa M,Takeoka K,Fukutsuka K,|

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation S...
https://doi.org/10.1016/j.clml.2020.09.007
Clinical Lymphoma, Myeloma & Leukemia; Kumar A, Bantilan KS et. al.

Feb 9th, 2021 - Minimal residual disease (MRD) monitoring has been used to identify early molecular relapse and predict clinical relapse in mantle cell lymphoma (MCL). Few published data exist in MCL on the performance of next-generation sequencing-based assay of...

see more →

News  501 results

First CAR T-cell Therapy for Mantle Cell Lymphoma Fills Unmet Need
https://www.medscape.com/viewarticle/943428

Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...

CAR T for All R/R DLBCL Patients: The Jury Is Still Out
https://www.medscape.com/viewarticle/939947

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
https://www.staging.medscape.com/viewarticle/939270

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
https://www.medscape.com/viewarticle/939270

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

Mantle Cell Lymphoma: Identifying Patients With Indolent Disease
https://www.staging.medscape.com/viewarticle/937175

Sep 9th, 2020 - Dr Eduardo Sotomayor Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and which should receive aggressive t...

see more →